New COVID-19 drug SIR1-365 tested for safety in hospitalized patients

NCT ID NCT04622332

First seen Nov 12, 2025 · Last updated May 16, 2026 · Updated 29 times

Summary

This early-stage trial tested the safety of an experimental drug called SIR1-365 in 45 hospitalized adults with severe COVID-19. Participants received either the drug or a placebo, and researchers monitored side effects and signs of inflammation. The goal was to see if the drug is safe enough for further testing, not to prove it cures the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONA VIRUS INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Aga Khan University Hospital

    Karachi, Sindh, 74800, Pakistan

  • Baptist Medical Center

    Jackson, Mississippi, 39202, United States

  • Dow University Hospital, Ojha Karachi

    Karachi, Sindh, 74200, Pakistan

  • Hospital Civil Fray Antonio Alcalde

    Guadalajara, Jalisco, 14050, Mexico

  • Hospital Universitario "Dr. José Eleuterio González"

    Monterrey, Nuevo León, 64460, Mexico

  • Media Sur - Medica Sur Tlalpan

    Tlalpan, Mexico City, 14050, Mexico

  • OSF St. Francis Medical Center

    Peoria, Illinois, 61637, United States

  • Sindh Infectious Disease Hospital

    Karachi, Sindh, 74200, Pakistan

  • Triple O Research Institute

    West Palm Beach, Florida, 33407, United States

Conditions

Explore the condition pages connected to this study.